Already a Bloomberg.com user?
Sign in with the same account.
Merck KGaA, the German maker of the cancer drug Erbitux, raised its full year forecast after second-quarter profit rose 14 percent as the euro’s decline boosted sales and demand for medicines increased.
On Air Now
Charlie Rose Watch Now
Next
Bloomberg West